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Abstract
Background: Oxidative stress plays an underlying pathophysiologic role in the development of diabetes complications. The
aim of this study was to investigate peroxiredoxin 4 (Prx4), a proposed novel biomarker of oxidative stress, and its
association with and capability as a biomarker in predicting (cardiovascular) mortality in type 2 diabetes mellitus.
Methods: Prx4 was assessed in baseline serum samples of 1161 type 2 diabetes patients. Cox proportional hazard models
were used to evaluate the relationschip between Prx4 and (cardiovascular) mortality. Risk prediction capabilities of Prx4 for
(cardiovascular) mortality were assessed with Harrell’s C statistic, the integrated discrimination improvement and net
reclassification improvement.
Results: Mean age was 67 and the median diabetes duration was 4.0 years. After a median follow-up period of 5.8 years, 327
patients died; 137 cardiovascular deaths. Prx4 was associated with (cardiovascular) mortality. The Cox proportional hazard
models added the variables: Prx4 (model 1); age and gender (model 2), and BMI, creatinine, smoking, diabetes duration,
systolic blood pressure, cholesterol-HDL ratio, history of macrovascular complications, and albuminuria (model 3). Hazard
ratios (HR) (95% CI) for cardiovascular mortality were 1.93 (1.57 – 2.38), 1.75 (1.39 – 2.20), and 1.63 (1.28 – 2.09) for models 1,
2 and 3, respectively. HR for all-cause mortality were 1.73 (1.50 – 1.99), 1.50 (1.29 – 1.75), and 1.44 (1.23 – 1.67) for models 1,
2 and 3, respectively. Addition of Prx4 to the traditional risk factors slightly improved risk prediction of (cardiovascular)
mortality.
Conclusions: Prx4 is independently associated with (cardiovascular) mortality in type 2 diabetes patients. After addition of
Prx4 to the traditional risk factors, there was a slightly improvement in risk prediction of (cardiovascular) mortality in this
patient group.
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Introduction
The importance of identifying patients with diabetes mellitus at
high risk for cardiovascular events and mortality has been pointed
out extensively in guidelines of the ADA/AHA and ESC/EASD
[1,2]. Risk assessment based on biomarkers such as NT-proBNP,
and imaging such as coronary artery calcium imaging and carotid
intima-media thickness might be useful markers possibly adding
predictive value to traditional risk estimates. Important athero-
genic factors in the development of diabetes-related morbidity and
mortality are advanced glycation endproducts (AGEs) formed by
nonenzymatic glycation of proteins and during oxidative stress [3].
The hyperglycemic state, AGEs and the interaction of AGEs with
its receptor RAGE (the so-called AGE-RAGE axis) induce
production of reactive oxygen species and is thought to play an
important underlying pathophysiologic role in the development of
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diabetes complications, both microvascular and cardiovascular [4–
7].
All aerobic organisms have a number of antioxidant proteins as
a protection mechanism against oxidative stress. Peroxiredoxin
enzymes are thiol-dependent peroxidases and part of a family of
proteins present in aerobic organisms, responsible for the
degradation of endogenously generated peroxides [8–10]. These
peroxiredoxin family members are distributed to potential sites of
reactive oxygen radicals production: the cytosol, mitochondria,
peroxisomes and in plasma [8]. Overexpression or upregulation of
peroxiredoxins is associated with higher levels of oxidative stress,
suggesting a secondary respons of peroxiredoxins to oxidative
stress [8,11–13]. Six isoforms of peroxiredoxins have been
described in mammals; peroxiredoxin 4 (Prx4) is the only isoform
detectable in serum [14]. Animal models of diabetes mellitus have
shown changes of expression or oxidation state of Prx4 in
pancreatic islet cells [13,15–17]. No serum levels of Prx4 have
been measured before in animal models neither in human with
type 2 diabetes mellitus (T2DM). Serum Prx4 has been proposed
as a biomarker of oxidative stress in patients with a sepsis [18,19].
Synovial tissue Prx4 showed an increased expression in patients
with rheumatoid arthritis, another inflammatory disease [20].
Recently, Prx4 have been studied in a general Dutch sample,
drawn from the general population and included subjects with
microalbuminuria [21]. This study showed that elevated serum
Prx4 levels were associated with a higher risk of cardiovascular
diseases, cardiovascular mortality as well as all-cause mortality and
slightly improved risk prediction. The aim of this study was to
prospectively investigate whether Prx4 is independently associated
with cardiovascular and all-cause mortality and whether it could
potentially be a new cardiovascular biomarker in patients with
T2DM.
Materials and Methods
Study group and design
The included patients in our study are type 2 diabetic patients
participating in a shared care project of the Zwolle Outpatient
Diabetes project Integrating Available Care (ZODIAC) study.
This project started in 1998 in Zwolle, The Netherlands, is still
ongoing and has been described in detail previously [22]. In short,
the objective of the ZODIAC study was to investigate the effects of
a shared-care project for type 2 diabetic patients. Sixty-one general
practitioners participated. The present study incorporates two
cohorts from the ZODIAC study. The first cohort contained 1143
patients and started in 1998. The second cohort contained 546
patients and started in 2001, leaving a combined cohort of 1689
unique patients included in the current study. Baseline character-
istics and mortality rates of the first cohort were similar to these of
the second cohort. The ZODIAC study was approved by the
medical ethics committee of the Isala Clinics in Zwolle, the
Netherlands and all patients gave their written informed consent.
Data collection
Clinical data were obtained from medical records at the time of
inclusion in the ZODIAC study, which consisted of a complete
medical history including macrovascular complications, medica-
tion use, diabetes duration and smoking history. Patients were
considered to have macrovascular complications when they had a
history of angina pectoris, myocardial infarction, percutaneous
transluminal coronary angioplasty, coronary artery bypass graft-
ing, stroke or transient ischemic attack. Laboratory and physical
assessment data, such as glycated hemoglobin (HbA1c), non-fasting
lipid profile, serum creatinine, albuminuria (albumin-to-creatinine
ratio), body mass index (BMI), and blood pressure were collected
annually. Blood pressure was measured twice with a Welch Allyn
Sphygmomanometer in the supine position after at least five
minutes of rest. For each visit the mean blood pressure of two
recordings was calculated.
Of the 1689 included patients, 1374 samples were eligible for
further analyses to measure Prx4. Complete information on Prx4
and potential confounders in this patient group was available for
1161 patients.
Serum Peroxiredoxin 4
Prx4 levels were measured in non-fasting serum samples
collected at baseline and stored at –80uC until analysis in 2010.
Because the performance of one freeze-thaw cycle has no
consequences for assessing Prx4 levels, no influence of frozen
storage on the assessed levels is to be expected [18]. Prx4 levels
were measured with a validated immunoluminometric sandwich
assay [18]. In the development of this assay, immunogenic
peptides were selected from the N-terminal part of the Prx4
epitope. The immunoassay uses two monoclonal mouse antibodies
both directed against amino acids 39 to 51 at this N-terminus of
human Prx4. According to the epitope distribution on the Prx4
amino acid sequence, the assay is useable for detection of Prx4
homomultimers and it excludes cross-reactivity with other
members of the Prx family.
The functional assay sensitivity (interassay coefficient of
variation ,20%) is 0.51 arbitrary U/L and the intraassay
coefficient of variation is ,8%. The assay reports Prx4 concen-
tration as arbitrary units per liter (U/L) and the limit of
quantitation was 0.38 arbitrary U/L.
Clinical endpoints
The clinical endpoints were cardiovascular and all-cause
mortality. In 2009, survival status and causes of death were
obtained from the local hospital information system and the
general practitioners concerning the ZODIAC cohort of 1998.
Survival status and causes of death of the ZODIAC cohort of 2001
were obtained in 2005. Causes of death were coded according to
the International Classification of Diseases, ninth revision (ICD-9).
Statistical analyses
SPSS version 16.0 (SAS Insitute, Cary, NC, USA) and STATA
version 11 (StataCorp, College Station, Texas USA) were used for
statistical analyses. Continuous variables are represented as mean
(standard deviation - SD) for normally distributed values and as
median (interquartile range - IQR) for non-normally distributed
variables. Prx4 levels below 0.38 arbitrary U/L were replaced by
an at random generated value between 0 and 0.38.
Cox proportional hazard models were used to investigate the
association between Prx4 and (cardiovascular) mortality. The
selected variables with possible confounding effects were age,
gender, BMI, serum creatinine, smoking, diabetes duration,
systolic blood pressure, cholesterol-HDL ratio, history of macro-
vascular complications, and albuminuria. Four models were
chosen: a crude model including only Prx4 (model 1), a model
with age and gender as additional confounders (model 2), a fully
adjusted model (model 3), and finally a model that contained all
the selected confounders except Prx4 (model 4).
Prx4 and serum creatinine were logarithmically transformed
because of skewed distribution of the data.
The ph-test was used in combination with inspection of the
Schoenfeld residuals to test the assumption of proportional hazards
at baseline. Calibration was investigated using the Groennesby
and Borgan test, assessing the goodness of fit and determining how
Peroxiredoxin 4 and Mortality in Type 2 Diabetes
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well the predicted probabilities agree with the observed risk. When
the average predicted risk matches the proportion that actually
develops disease within subgroups of a prospective cohort, the
model is considered well calibrated [23]. In case of a significant
association between Prx4 and (cardiovascular) mortality, the
following analyses were performed. Harrell’s C statistic, a rank-
based measure, was used to compare how well the different models
predict mortality [24]. The higher the value the better the model
predicts mortality. Furthermore, the integrated discrimination
improvement (IDI) and the net reclassification improvement (NRI)
using 10%, 20%, and 30% cut-off values, were calculated [25].
Both, the IDI and the NRI are designed to evaluate the
improvement in prediction by novel markers. They can be
interpreted as the difference between model-based probabilities for
events and non events for models with and without Prx4. The IDI
is a global measure of correct reclassification regarding all possible
cut-off values, while the NRI gives the reclassification improve-
ment for a number of cut-off values. The 95% confidence intervals
for Harrell’s C, IDI, and NRI are given in the results.
Results
Baseline characteristics of the 1161 included patients are
presented in strata according to Prx4 levels (table 1). 137 Patients
had a Prx4 level below 0.38 arbitrary U/L. Median (interquartile
range, IQR) serum level of Prx4 was 0.79 (0.53 – 1.25) arbitrary
U/L. Patients with Prx4 above the median were older, had a
higher BMI, lower eGFR, lower HDL cholesterol levels, higher
HbA1c levels, higher prevalence of albuminuria and less frequently
received lipid-lowering drugs, although the percentage of smokers
was lower. After a median (IQR) follow-up of 5.8 (3.1– 10.1) years,
327 (28%) patients had died, of which 137 (42%) were attributable
to cardiovascular disease.
The survivors had lower median (IQR) baseline levels of Prx4
compared to the non-survivors [0.71 (0.48 – 1.05) arbitrary U/L]
versus [1.05 (0.65 – 1.59) arbitrary U/L]; p,0.001.
Inspection of the Schoenfeld residuals and Stata’s ph-test
showed no violations of the assumption of proportional hazards.
The goodness of fit analyses indicated that the models for
cardiovascular mortality as well as for all-cause mortality were
well calibrated.
Increased levels of Prx4 were associated with higher rates of
cardiovascular and all-cause mortality (Table 2). These associa-
tions persisted after adjustment for confounders in models 2 and 3.
The Harrel’s C values, as presented in Table 2, show that with
increasing numbers of confounders, the better the model predicted
cardiovascular mortality and all-cause mortality. However, no
differences in the C values were observed between models 3 (the
fully adjusted model) and model 4 (the fully adjusted model
without Prx4).
Furthermore, the IDI and NRI were positive in models 2 and 3
for both cardiovascular and all-cause mortality.
Concerning cardiovascular mortality, changes in classification
for Prx4 with age and gender are shown in table 3 and with all
known risk factors in table 4. For example: without adjusting for
Prx4, 25 patients had been classified in the cardiovascular
mortality risk group of , 10%. However, when Prx4 was added
to this risk model, 6 patients were reclassified into the cardiovas-
cular mortality risk group of 10 – 20%. Furthermore, out of a total
number of 577 patients in the survivor group: 41, 2 and 1 patient(s)
were reclassified into another category after adding Prx4 to the
model.
Table 5 and 6 show the changes in classification for Prx4 with
age and gender respectively with all known risk factors concerning
all-cause mortality.
Table 1. Baseline characteristics.
Baseline characteristic Total n = 1161 Group 1 Prx4 , median* Group 2 Prx4 . median p-value
Age (years) 67 (12) 65 (11) 68 (11) ,0.0011
Gender male (%) 522 (45) 276 (48) 246 (42) 0.093
Diabetes duration (years) 4.0 [2.0 – 9.0] 4.0 [2.0 – 9.0] 4.0 [2.0 – 9.0] 0.432
eGFR (Cockcroft-Gault) (ml/min) [n =1022] 72 [57 – 92] 73 [58 – 94] 70 [55 – 90] 0.0082
BMI (kg/m2) 28.7 [25.8 – 32.0] 28.1 [25.4 – 31.3] 29.2 [26.0 – 32.6] ,0.0012
Smoking (%) 220 (19) 125 (22) 95 (16) 0.033
Systolic blood pressure (mmHg) 152 (24) 151 (24) 153 (24) 0.371
HbA1c (%) 7.0 [6.2 – 8.1] 6.8 [6.2 – 7.9] 7.1 [6.3 – 8.2] 0.012
Albuminuria (%) 455 (39) 182 (31) 273 (47) ,0.0013
Total cholesterol (mmol/l) 5.4 [4.8 – 6.2] 5.5 [4.8 – 6.2] 5.4 [4.7 – 6.2] 0.252
HDL – cholesterol (mmol/l) 1.2 [1.0 – 1.4] 1.2 [1.0 – 1.4] 1.1 [0.9 – 1.3] 0.0032
Cholesterol – HDL ratio 4.7 [3.8 – 5.8] 4.7 [3.8 – 5.6] 4.8 [3.9 – 6.0] 0.022
Macrovascular complications (%) 413 (36) 195 (34) 218 (38) 0.163
Receiving lipid-lowering drugs (statins) (%) 187 (16) 110 (19) 77 (13) 0.013
Receiving trombocyte aggregation inhibitor
(%)
185 (16) 92 (16) 93 (16) 0.943
Receiving ACE-I/ARB (%) 313 (27) 160 (28) 153 (26) 0.693
Abbreviations: eGFR, estimated glomerular filtration rate; BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; ACE-I, angiotensin
converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*) Median Prx4 (U/L): 0.79 [0.53 – 1.25].
Data are means (SD), medians [interquartile range], or n (%). P-values show (non)significance of group 2 compared to group 1. 1) Student’s t-test. 2) Mann-Whitney U
test. 3) Fisher’s Exact test.
doi:10.1371/journal.pone.0089719.t001
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Discussion
Our study provides the first evidence that the free serum
antioxidant Prx4 is independently associated with cardiovascular
and all-cause mortality in patients with T2DM after long-term
follow up. Prx4 could play a role in the prediction of
(cardiovascular) mortality in T2DM, although there was no
relevant added beneficial effect of Prx4 compared to a fully
adjusted model. Adding Prx4 to age and gender (model 2) had a
comparable predictive value as adding Prx4 to the combined
traditional cardiovascular risk factors (model 3).
Two recent studies showed that Prx4 has predictive capabilities
[21,26]. One was established for 30-days mortality in patients with
nonspecific complaints presenting at the emergency department
and the other study demonstrated the association between Prx4
and cardiovascular morbidity and mortality and all-cause mortal-
ity in a large general population with a median follow up time of
10.5 years [21,26]. No previous studies were performed in patients
with DM.
When compared to healthy controls, patients with inflammatory
conditions like sepsis had higher levels of circulating Prx4 [18,19].
Non-surviving patients with a sepsis have higher Prx4 levels
compared to the surviving patients and Prx4 is correlated with
markers of infection and inflammation, like procalcitonin, C-
reactive protein (CRP) and interleukin 6 [19,20]. Additional
information about correlations with antioxidant markers and with
oxidative damage markers would be useful to establish the use of
Prx4 as a novel biomarker of oxidative stress.
Table 2. Hazard ratios for cardiovascular and all-cause mortality of the logarithmically transformed Prx4.
Model 1 Model 2 Model 3 Model 4
Cardiovascular mortality
Hazard ratio [95% CI] 1.93 [1.57 – 2.38] 1.75 [1.39 – 2.20] 1.63 [1.28 – 2.09] n.a.
Harrell’s C [95% CI] 0.65 [0.61 – 0.70] 0.77 [0.73 – 0.81] 0.82 [0.78 – 0.85] 0.81 [0.77 – 0.84]
IDI % [95% CI] p-value n.a. 1.97 [1.03 – 2.91] 0.00004 0.97 [0.16 – 1.77] 0.018 n.a.
NRI % [95% CI] n.a. 11.78 [2.35 – 21.21] 6.48 [0.00 – 13.33] n.a.
All-cause mortality
Hazard ratio [95% CI] 1.73 [1.50 – 1.99] 1.50 [1.29 – 1.75] 1.44 [1.23 – 1.67] n.a.
Harrell’s C [95% CI] 0.64 [0.61 – 0.67] 0.79 [0.76 – 0.81] 0.81 [0.78 – 0.83] 0.80 [0.77 – 0.82]
IDI % [95% CI] p-value n.a. 2.38 [1.41 – 3.34] , 0.00001 1.63 [0.82 – 2.44] 0.00009 n.a.
NRI % [95% CI] n.a. 6.82 [2.42 – 11.23] 8.03 [3.81 – 12.24] n.a.
Comparison of predictive capability of models for mortality risk prediction as determined by the Harrell’s C statistic, the IDI, and NRI.
Abbreviations: Prx4, peroxiredoxin 4; HR, hazard ratio; CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement; NA, not
applicable.
Cox regression models: Model 1: crude model with Prx4; Model 2: adjusted for age and gender; Model 3: adjusted for age, gender, smoking (dichotomous), body mass
index, systolic blood pressure, duration of diabetes, serum creatinine level, cholesterol-HDL ratio, macrovascular complications (dichotomous), albuminuria
(dichotomous); Model 4: all selected confounders without Prx4.
doi:10.1371/journal.pone.0089719.t002
Table 3. Changes in classification for Prx4 with age and
gender (cardiovascular mortality).
Age, gender and Prx4
Age and
gender , 10% 10 – 20% 20 – 30% .= 30% Total
deceased
, 10% 19 6 25
10 – 20% 3 49 13 1 66
20 – 30% 8 16 7 31
.= 30% 2 13 15
Total 22 63 31 21 137
survivals
, 10% 533 41 2 1 577
10 – 20% 64 192 41 1 298
20 – 30% 2 27 62 23 114
.= 30% 2 1 8 24 35
Total 601 261 113 49 1024
NRI % [95% CI] 11.78 [2.35 – 21.21]
doi:10.1371/journal.pone.0089719.t003
Table 4. Changes in classification for Prx4 with all known risk
factors (cardiovascular mortality).
All known risk factors and Prx4
All risk
factors , 10% 10 – 20% 20 – 30% .= 30% Total
deceased
, 10% 21 3 24
10 – 20% 1 29 8 38
20 – 30% 3 20 2 25
.= 30% 4 46 50
Total 22 35 32 48 137
survivals
, 10% 671 22 693
10 – 20% 43 127 14 1 185
20 – 30% 2 10 49 12 73
.=30% 1 12 60 73
Total 716 160 75 73 1024
NRI % [95% CI] 6.48 [0.00 – 13.33]
doi:10.1371/journal.pone.0089719.t004
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In response to free oxygen radical production in T2DM,
secretion of thiol-dependent peroxidases will increase to partici-
pate in the removal of these reactive oxygen species. It is
hypothesized that the intracellular removal of hydrogen peroxides
by Prx4 and secretion of the enzyme is proportionally upregulated
in response to the surrounding oxidative stress [10,14]. Oxidative
stress also causes endothelial damage, which possibly could result
in additional endothelial tissue leakage of Prx4, contributing to
even higher levels of serum Prx4. It still has to be investigated if
Prx4 is actively removing hydrogen peroxides in the circulation.
Perhaps, Prx4, being part of the antioxidant defense system, can
rather be considered as a marker of endothelial cell damage and
therefore would indirectly be linked to oxidative stress.
Our study had a few limitations. Patients with higher levels of
Prx4 in our study revealed several characteristics that may have
influenced Prx4 or oxidative stress in general. These include older
age, higher prevalence of albuminuria, higher BMI, lower levels of
HDL and less use of lipid lowering drugs like statins. However,
even after adjustment for most of these confounders, the
associations between Prx4 and mortality remained significant.
Furthermore, our analyses were performed in only 1161 out of
the initially 1689 included patients, so selection bias may have
occurred. Secondly, because we only adjusted for a single baseline
Prx4 value, we were not able to adjust for potential variability in
Prx4 concentrations. Whether sequential measurements of Prx4
will result in a better prediction of mortality in patients with
diabetes remains to be investigated. Mortality data ranging up to
2009 for the whole population would have been of additional
value. We also acknowledge the lack of data on CRP or IL-6 as a
limitation. The addition of CRP or IL-6 could have provided
insight into the pathophysiology of and the interface between
inflammation and oxidative stress. Prx4 might behave like an acute
phase reactant, but also as a biomarker, regardless of the causal
pathway.
Finally, care must be taken in interpreting the values of the IDI
and NRI, because these measures are dependent on the
prevalence of the number of events and are not developed in
the context of censored data. Besides this, there is no consensus
regarding the interpretation of the magnitude of both measures.
Strengths of our study were the number and completeness of
confounders, its prospective design and a long follow up period. It
is also the first study of Prx4 in a large group of patients, including
over 1000 T2DM patients.
To conclude, Prx4 is a circulating antioxidant and is indepen-
dently associated with increased risk of cardiovascular and all-
cause mortality in T2DM. Future studies are needed to answer the
question whether Prx4, as a novel biomarker of oxidative stress,
may be a new valuable cardiovascular predictor useful for risk
stratification in T2DM.
Author Contributions
Performed the experiments: KHG NK. Analyzed the data: EGG.
Contributed reagents/materials/analysis tools: J. Schulte J. Struck. Wrote
the paper: EGG AA GWDL KJJH ROBG SJLB HJGB.
References
1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. (2007) Primary
prevention of cardiovascular diseases in people with diabetes mellitus: a scientific
statement from the American Heart Association and the American Diabetes
Association. Diabetes Care 30: 162–172.
2. Ryde´n L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. (2013) ESC
guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in
collaboration with the EASD: the task force on diabetes, pre-diabetes, and
cardiovascular diseases of the European Society of Cardiology (ESC) and
developed in collaboration with the European Association for the Study of
Diabetes (EASD). Eur Heart J 34: 3035–87.
3. Brownlee M (2005) The pathobiology of diabetic complications: a unifying
mechanism. Diabetes 54: 1615–1625.
4. Rains JL, Jain SK (2011) Oxidative stress, insulin signaling, and diabetes. Free
Radic Biol Med 50: 567–575.
5. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental
mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842–
53.
6. Rolo AP, Palmeira CM (2006) Diabetes and Mitochondrial function: role of
hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212: 167–178.
Table 5. Changes in classification for Prx4 with age and
gender (all-cause mortality).
Age, gender and Prx4
Age and
gender , 10% 10 – 20% 20 – 30% .= 30% Total
deceased
, 10% 14 2 16
10 – 20% 2 18 4 24
20 – 30% 4 14 8 26
.= 30% 1 3 6 251 261
Total 17 27 24 259 327
survivals
, 10% 295 12 2 309
10 – 20% 38 118 23 3 182
20 – 30% 7 26 64 16 113
.= 30% 1 10 27 192 230
Total 341 166 116 211 834
NRI% [95% CI] 6.82[2.42 – 11.23]
doi:10.1371/journal.pone.0089719.t005
Table 6. Changes in classification for Prx4 with all known risk
factors (all-cause mortality).
All known risk factors and Prx4
All risk
factors , 10% 10 – 20% 20 – 30% .= 30% Total
deceased
, 10% 19 3 22
10 – 20% 1 8 7 16
20 – 30% 1 4 13 10 28
.= 30% 1 1 4 256 261
Total 21 16 24 266 327
survivals
, 10% 367 17 1 1 386
10 – 20% 34 109 18 161
20 – 30% 1 21 59 11 92
.=30% 8 18 169 195
Total 402 155 96 181 834
NRI% [95% CI] 8.03 [3.81 – 12.24]
doi:10.1371/journal.pone.0089719.t006
Peroxiredoxin 4 and Mortality in Type 2 Diabetes
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e89719
7. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ
Res 107: 1058–1070.
8. Wood ZA, Schro¨der E, Harris JR, Poole LB (2003) Structure, mechanism and
regulation of peroxiredoxins. Trends Biochem Sci 28: 32–40.
9. Valko M, Leibfritz D, Moncol J, Cronin M, Mazur M, et al. (2007) Free radicals
and antioxidants in normal physiological functions and human disease. Int J
Biochem Cell Biol 39: 44–84.
10. Tavender TJ, Bulleid NJ (2010) Peroxiredoxin IV protects cells from oxidative
stress by removing H2O2 produced during disulphide formation. J Cell Science
123: 2672–2679.
11. Fujii J, Ikeda Y (2002) Advances in our understanding of peroxiredoxin, a
multifunctional, mammalian redox protein. Redox Rep 7: 123–130.
12. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, et al. (2002) Proteomics
analysis of cellular response to oxidative stress: evidence for in vivo over-
oxidation of peroxiredoxins at their active site. J Biol Chem 277: 19396–19401.
13. Ding Y, Yamada S, Wang KY, Shimajiri S, Guo X, et al. (2010) Overexpression
of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by
suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox
Signal 13: 1477–1490.
14. Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N (2000) Peroxiredoxin
IV is a secretable protein with heparin-binding properties under reduced
conditions. J Biochem 127: 493–501.
15. Xie X, Li S, Liu S, Lu Y, Shen P, Ji J (2008) Proteomic analysis of mouse islets
after multiple low-dose streptozotocin injection. Biochim Biophys Acta 1784:
276–284.
16. Dreja T, Jovanovic Z, Rasche A, Kluge R, Herwig R, et al. (2010) Diet-induced
gene expression of isolated pancreatic islets from a polygenic mouse model of the
metabolic syndrome. Diabetologia 53: 309–320.
17. Jiang YL, Ning Y, Ma XL, Liu YY, Wang Y, et al. (2011) Alteration of the
proteome profile of the pancreas in diabetic rats induced by streptozotocin. Int J
Mol Med 28: 153–160.
18. Schulte J, Struck J, Bergmann A, Ko¨hrle J (2010) Immunoluminometric assay
for quantification of peroxiredoxin 4 in human serum. Clin Chim Acta 411:
1258–1263.
19. Schulte J, Struck J, Ko¨hrle J, Mu¨ller B (2011) Circulating levels of peroxiredoxin
4 as a novel biomarker of oxidative stress in patients with sepsis. Shock 35: 460–
465.
20. Chang X, Cui Y, Zong M, Zhao Y, Yan X, et al. (2009) Identification of proteins
with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol
36: 872–880.
21. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, et al. (2012)
Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of
incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 1:
e002956.
22. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, et al.
(2003) Prevalence, incidence and mortality of type 2 diabetes mellitus revisited.
A prospective population-based study in The Netherlands (ZODIAC-1). Eur J of
Epidemiol 18: 793–800.
23. May S, Hosmer DW (1998) A simplified method of calculation an overall
goodness of-fit test for the Cox proportional hazards model. Lifetime Data Anal
4: 109–120.
24. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues
in developing models, evaluating assumptions and adequacy, and measuring and
reducing errors. Stat Med 15: 361–387.
25. Pencine MJ, D’Agostino RB, Vasan RS (2010) Statistical methods for assessment
of added usefulness of new biomarkers. Clin Chem Lab Med 48: 1703–1711.
26. Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, et al. (2011) Copeptin and
Peroxiredoxin-4 independently predict mortality in patients with nonspecific
complaints presenting to the emergency department. Acad Emerg Med 18: 851–
859.
Peroxiredoxin 4 and Mortality in Type 2 Diabetes
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e89719
